The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C value - an Evaluation of Rosuvastatin therapY compared with atorvastatin

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C value - an Evaluation of Rosuvastatin therapY compared with atorvastatin

Autor Fonseca, FAH Google Scholar
Ruiz, A. Google Scholar
Cardona-Munoz, E. G. Google Scholar
Silva, J. M. Google Scholar
Fuenmayor, N. Google Scholar
Marotti, M. Google Scholar
DISCOVERY PENTA investigators Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Pontificia Univ Javeriana
Univ Guadalajara
Univ Coimbra
Hosp Miguel Perez Carreno
AstraZeneca
Resumo Background. International guidelines emphasize the need to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels in order to reduce morbidity and mortality associated with coronary heart disease (CHD). However, many patients with hypercholesterolemia fail to achieve LDL-C goals on treatment.Objective: the primary objective was to compare the efficacy of rosuvastatin and atorvastatin for enabling patients to achieve National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goals. Secondary objectives were European LDL-C goal achievement, changes in the lipid profile, and safety. Research design and methods: This 12-week, multicenter, multinational, randomized, open-label trial compared the efficacy and safety of rosuvastatin 10 mg with atorvastatin 10 mg in statin-naive and switched patients with primary hypercholesterolemia from Brazil, Colombia, Mexico, Portugal, and Venezuela.Results: A total of 1124 patients with similar baseline characteristics were randomized to the two treatment groups. After 12 weeks of treatment, a significantly greater percentage of patients receiving rosuvastatin 10mg compared with atorvastatin 10 mg achieved NCEP ATP III LDL-C goals (71.2% vs 61.4%, p < 0.001), 1998 European LDL-C goals (73.5% vs 59.2%, p < 0.001) and 2003 European LDL-C goals (58.9% vs 44.6%, p < 0.001). Rosuvastatin treatment was associated with significant reductions in LDL-C and total cholesterol (TC) and, in statin-naive patients, a significant increase in high-density lipoprotein cholesterol (HDL-C) compared with atorvastatin treatment. Both treatments were well tolerated with a similar incidence of adverse events. Clinically significant elevations in creatinine, creatine kinase or hepatic transaminases were low and similar between treatment groups.Conclusions: Rosuvastatin 10 mg is significantly more effective at achieving NCEP ATP III and European LDL-C goals, lowering LDL-C and TC in both naive and switched patients and increasing HDL-C in naive patients than atorvastatin 10 mg, with a similar safety and tolerability profile. This study also provides evidence regarding the comparative effects of rosuvastatin versus atorvastatin in Latin American and Portuguese populations.
Palavra-chave atorvastatin
cardiovascular disease
coronary heart disease
high-density lipoprotein cholesterol
low-density lipoprotein cholesterol
rosuvastatin
triglycerides
Idioma Inglês
Data de publicação 2005-08-01
Publicado em Current Medical Research and Opinion. Newbury: Librapharm, v. 21, n. 8, p. 1307-1315, 2005.
ISSN 0300-7995 (Sherpa/Romeo, fator de impacto)
Publicador Librapharm
Extensão 1307-1315
Fonte http://dx.doi.org/10.1185/030079905X56529
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000231469300021
Endereço permanente http://repositorio.unifesp.br/handle/11600/28421

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta